Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun 14;45(6):525-533.
doi: 10.3760/cma.j.cn121090-20240608-00214.

[Chinese expert consensus on the diagnosis and treatment of acute graft-versus-host disease after hematopoietic stem cell transplantation (2024)]

[Article in Chinese]
Hematopoietic Stem Cell Application Group, Chinese Society of Hematology, Chinese Medical Association

[Chinese expert consensus on the diagnosis and treatment of acute graft-versus-host disease after hematopoietic stem cell transplantation (2024)]

[Article in Chinese]
Hematopoietic Stem Cell Application Group, Chinese Society of Hematology, Chinese Medical Association. Zhonghua Xue Ye Xue Za Zhi. .

Abstract
in English, Chinese

Despite the continuous improvement in the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT), acute graft-versus-host disease (GVHD) remains a major complication and cause of death. In recent years, with the emergence of new drugs for the prevention and treatment of acute GVHD and the update of a series of clinical studies, there have been varying degrees of changes in the routine prevention and treatment regimens for acute GVHD. Based on the main research achievements and the accumulation of clinical experience in this field in recent years, this consensus further updates the "The Consensus on Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Diseases in China-Acute Graft-Versus-Host Disease (2020) .

尽管异基因造血干细胞移植（allo-HSCT）的疗效不断改善，急性移植物抗宿主病（GVHD）仍然是主要的合并症和死亡原因。近年来，随着急性GVHD防治新型药物的出现及系列临床研究的更新，常规急性GVHD预防及治疗方案有着不同程度的变化。基于近年来在该领域的主要研究成果和临床经验的积累，本共识在《中国异基因造血干细胞移植治疗血液系统疾病专家共识——急性移植物抗宿主病（2020年）》基础上做进一步更新。.

Keywords: Acute graft-versus-host disease; Allogeneic hematopoietic stem cell transplantation.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Schoemans HM, Lee SJ, Ferrara JL, et al. EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment[J] Bone Marrow Transplant. 2018;53(11):1401–1415. doi: 10.1038/s41409-018-0204-7. - DOI - PMC - PubMed
    1. Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report[J] Biol Blood Marrow Transplant. 2015;21(3):389–401. doi: 10.1016/j.bbmt.2014.12.001. - DOI - PMC - PubMed
    1. Han LJ, Wang Y, Fan ZP, et al. Haploidentical transplantation compared with matched sibling and unrelated donor transplantation for adults with standard-risk acute lymphoblastic leukaemia in first complete remission[J] Br J Haematol. 2017;179(1):120–130. doi: 10.1111/bjh.14854. - DOI - PubMed
    1. Luo Y, Xiao H, Lai X, et al. T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCT[J] Blood. 2014;124(17):2735–2743. doi: 10.1182/blood-2014-04-571570. - DOI - PMC - PubMed
    1. Yu S, Huang F, Wang Y, et al. Haploidentical transplantation might have superior graft-versus-leukemia effect than HLA-matched sibling transplantation for high-risk acute myeloid leukemia in first complete remission: a prospective multicentre cohort study[J] Leukemia. 2020;34(5):1433–1443. doi: 10.1038/s41375-019-0686-3. - DOI - PubMed

Publication types